Rachel Clark Sisodia, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genital Neoplasms, Female | 10 | 2024 | 523 | 3.190 |
Why?
|
Fallopian Tube Neoplasms | 5 | 2022 | 324 | 1.870 |
Why?
|
Ovarian Neoplasms | 19 | 2023 | 4838 | 1.810 |
Why?
|
Carcinoma, Endometrioid | 9 | 2023 | 271 | 1.460 |
Why?
|
Vulvar Neoplasms | 4 | 2024 | 272 | 1.100 |
Why?
|
Peritoneal Neoplasms | 5 | 2023 | 665 | 1.060 |
Why?
|
Endometrial Neoplasms | 11 | 2023 | 1353 | 0.970 |
Why?
|
Carcinosarcoma | 6 | 2023 | 108 | 0.830 |
Why?
|
Hysterectomy | 6 | 2022 | 927 | 0.790 |
Why?
|
Anesthesia Department, Hospital | 1 | 2021 | 68 | 0.750 |
Why?
|
Uterine Neoplasms | 8 | 2023 | 1513 | 0.670 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2021 | 360 | 0.640 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2015 | 484 | 0.610 |
Why?
|
Genetic Counseling | 1 | 2020 | 600 | 0.560 |
Why?
|
Physicians, Primary Care | 1 | 2021 | 591 | 0.490 |
Why?
|
Social Support | 1 | 2023 | 2118 | 0.450 |
Why?
|
Psychometrics | 2 | 2021 | 3002 | 0.450 |
Why?
|
Cystadenocarcinoma, Serous | 5 | 2023 | 450 | 0.430 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2023 | 221 | 0.420 |
Why?
|
Fallopian Tubes | 2 | 2022 | 182 | 0.410 |
Why?
|
Lymph Node Excision | 7 | 2023 | 1261 | 0.410 |
Why?
|
Pelvis | 4 | 2023 | 730 | 0.380 |
Why?
|
Electronic Health Records | 4 | 2022 | 4468 | 0.380 |
Why?
|
Anesthesiology | 1 | 2021 | 1060 | 0.370 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3158 | 0.370 |
Why?
|
Data Collection | 1 | 2020 | 3341 | 0.370 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2023 | 2020 | 0.340 |
Why?
|
Menotropins | 1 | 2008 | 45 | 0.330 |
Why?
|
Quality of Life | 8 | 2023 | 12804 | 0.330 |
Why?
|
Female | 61 | 2024 | 380194 | 0.320 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 2 | 2015 | 198 | 0.320 |
Why?
|
Ovary | 2 | 2022 | 981 | 0.310 |
Why?
|
Anxiety | 1 | 2021 | 4297 | 0.300 |
Why?
|
Ovarian Follicle | 1 | 2008 | 247 | 0.290 |
Why?
|
Ovulation Induction | 1 | 2008 | 274 | 0.280 |
Why?
|
Follicle Stimulating Hormone | 1 | 2008 | 744 | 0.270 |
Why?
|
Neoplasm Staging | 18 | 2023 | 11031 | 0.260 |
Why?
|
Humans | 72 | 2024 | 744343 | 0.260 |
Why?
|
Massachusetts | 4 | 2023 | 8663 | 0.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11524 | 0.240 |
Why?
|
SEER Program | 10 | 2016 | 1508 | 0.240 |
Why?
|
Lymph Nodes | 4 | 2021 | 3474 | 0.230 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 59 | 0.230 |
Why?
|
Health Status Indicators | 2 | 2021 | 969 | 0.220 |
Why?
|
Middle Aged | 32 | 2023 | 213383 | 0.220 |
Why?
|
Fallopian Tube Diseases | 1 | 2022 | 62 | 0.210 |
Why?
|
Aged | 31 | 2023 | 163280 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.200 |
Why?
|
Teratoma | 1 | 2014 | 395 | 0.200 |
Why?
|
Carcinoma | 1 | 2013 | 2375 | 0.200 |
Why?
|
Osteoarthritis, Knee | 2 | 2022 | 1222 | 0.200 |
Why?
|
Pandemics | 1 | 2021 | 8388 | 0.200 |
Why?
|
Ovarian Diseases | 1 | 2022 | 139 | 0.190 |
Why?
|
Morpholines | 1 | 2014 | 571 | 0.190 |
Why?
|
Arthroplasty, Replacement, Knee | 2 | 2022 | 1458 | 0.190 |
Why?
|
Metrorrhagia | 1 | 2010 | 18 | 0.180 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2022 | 709 | 0.180 |
Why?
|
Aminopyridines | 1 | 2014 | 542 | 0.180 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 3479 | 0.180 |
Why?
|
Surgical Procedures, Operative | 2 | 2022 | 1876 | 0.180 |
Why?
|
Retrospective Studies | 21 | 2023 | 77449 | 0.180 |
Why?
|
Aged, 80 and over | 15 | 2023 | 57776 | 0.170 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 895 | 0.170 |
Why?
|
Medical Oncology | 3 | 2019 | 2265 | 0.170 |
Why?
|
Patient Readmission | 1 | 2013 | 3114 | 0.170 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 973 | 0.170 |
Why?
|
Health Education | 1 | 2015 | 1056 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17446 | 0.160 |
Why?
|
Osteoarthritis, Hip | 1 | 2022 | 412 | 0.150 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 379 | 0.150 |
Why?
|
Hydatidiform Mole | 1 | 2010 | 279 | 0.150 |
Why?
|
Attitude of Health Personnel | 2 | 2022 | 3843 | 0.150 |
Why?
|
Maternal Age | 1 | 2010 | 802 | 0.150 |
Why?
|
Health Facilities | 1 | 2022 | 573 | 0.150 |
Why?
|
Specialties, Surgical | 1 | 2022 | 391 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2021 | 9239 | 0.140 |
Why?
|
Referral and Consultation | 3 | 2020 | 3528 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2020 | 594 | 0.140 |
Why?
|
Activities of Daily Living | 2 | 2022 | 2418 | 0.130 |
Why?
|
Prospective Studies | 5 | 2023 | 53288 | 0.130 |
Why?
|
Adult | 19 | 2023 | 214055 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2503 | 0.130 |
Why?
|
Postoperative Care | 1 | 2022 | 1486 | 0.130 |
Why?
|
Burnout, Professional | 1 | 2023 | 694 | 0.120 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2728 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 2109 | 0.120 |
Why?
|
Lymphatic Metastasis | 5 | 2022 | 2924 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 975 | 0.120 |
Why?
|
Disability Evaluation | 1 | 2021 | 1827 | 0.120 |
Why?
|
Gynecologic Surgical Procedures | 2 | 2015 | 336 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2010 | 1607 | 0.120 |
Why?
|
Survival Rate | 10 | 2016 | 12788 | 0.120 |
Why?
|
Patient Positioning | 1 | 2016 | 324 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 7 | 2016 | 6538 | 0.120 |
Why?
|
Academic Medical Centers | 2 | 2022 | 2759 | 0.110 |
Why?
|
Ileus | 1 | 2013 | 58 | 0.110 |
Why?
|
Program Evaluation | 1 | 2022 | 2488 | 0.110 |
Why?
|
Myometrium | 1 | 2014 | 181 | 0.110 |
Why?
|
Placenta Accreta | 1 | 2016 | 225 | 0.110 |
Why?
|
Intraoperative Care | 1 | 2016 | 767 | 0.110 |
Why?
|
Epithelial Cells | 1 | 2014 | 3690 | 0.110 |
Why?
|
Video Recording | 1 | 2017 | 949 | 0.100 |
Why?
|
Self Care | 1 | 2017 | 786 | 0.100 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2016 | 506 | 0.100 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 3022 | 0.100 |
Why?
|
Perioperative Period | 1 | 2013 | 256 | 0.100 |
Why?
|
Cohort Studies | 5 | 2022 | 40561 | 0.100 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3086 | 0.100 |
Why?
|
Length of Stay | 4 | 2022 | 6309 | 0.100 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3923 | 0.100 |
Why?
|
Leiomyosarcoma | 1 | 2015 | 477 | 0.090 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2016 | 808 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2012 | 2291 | 0.090 |
Why?
|
Developing Countries | 1 | 2012 | 2815 | 0.090 |
Why?
|
Pleural Effusion | 1 | 2013 | 338 | 0.090 |
Why?
|
Proportional Hazards Models | 7 | 2016 | 12354 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1897 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1770 | 0.090 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1257 | 0.090 |
Why?
|
Analgesics, Opioid | 2 | 2023 | 3674 | 0.080 |
Why?
|
Gynecology | 1 | 2015 | 513 | 0.080 |
Why?
|
Clomiphene | 1 | 2008 | 72 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3952 | 0.080 |
Why?
|
Fertility Agents, Female | 1 | 2008 | 99 | 0.080 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 8642 | 0.080 |
Why?
|
Carcinoma, Papillary | 1 | 2013 | 783 | 0.080 |
Why?
|
Opioid-Related Disorders | 1 | 2023 | 2065 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2014 | 1198 | 0.080 |
Why?
|
Health Personnel | 1 | 2021 | 3218 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 4034 | 0.080 |
Why?
|
Disease-Free Survival | 4 | 2016 | 6895 | 0.080 |
Why?
|
Pregnancy, Multiple | 1 | 2008 | 217 | 0.080 |
Why?
|
Carboplatin | 2 | 2016 | 801 | 0.080 |
Why?
|
Prognosis | 9 | 2016 | 29063 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2278 | 0.070 |
Why?
|
Paclitaxel | 2 | 2014 | 1708 | 0.070 |
Why?
|
Patient Discharge | 2 | 2023 | 3313 | 0.070 |
Why?
|
Patients | 2 | 2023 | 900 | 0.070 |
Why?
|
Luteinizing Hormone | 1 | 2008 | 869 | 0.070 |
Why?
|
Image Enhancement | 1 | 2016 | 2921 | 0.070 |
Why?
|
Pregnancy Rate | 1 | 2008 | 643 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4567 | 0.060 |
Why?
|
Postoperative Period | 2 | 2022 | 1842 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2014 | 1956 | 0.060 |
Why?
|
Platinum Compounds | 1 | 2014 | 96 | 0.060 |
Why?
|
Radiotherapy | 3 | 2016 | 1533 | 0.060 |
Why?
|
United States | 11 | 2023 | 69872 | 0.060 |
Why?
|
Paget Disease, Extramammary | 1 | 2024 | 45 | 0.060 |
Why?
|
Surgical Wound Infection | 1 | 2013 | 1540 | 0.060 |
Why?
|
Reoperation | 1 | 2013 | 4201 | 0.060 |
Why?
|
Qualitative Research | 2 | 2022 | 2682 | 0.060 |
Why?
|
Young Adult | 4 | 2023 | 56430 | 0.060 |
Why?
|
Morphine Derivatives | 1 | 2023 | 44 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2016 | 3616 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2014 | 130 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2021 | 63114 | 0.060 |
Why?
|
Pregnancy | 5 | 2019 | 29144 | 0.050 |
Why?
|
Organoplatinum Compounds | 2 | 2015 | 408 | 0.050 |
Why?
|
Venous Thromboembolism | 1 | 2015 | 1671 | 0.050 |
Why?
|
Population Groups | 1 | 2023 | 209 | 0.050 |
Why?
|
Pain, Postoperative | 2 | 2023 | 1643 | 0.050 |
Why?
|
Hydromorphone | 1 | 2022 | 65 | 0.050 |
Why?
|
Mortality | 1 | 2013 | 2864 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2024 | 6364 | 0.050 |
Why?
|
Decompression | 1 | 2020 | 43 | 0.050 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 781 | 0.050 |
Why?
|
Signal Transduction | 1 | 2014 | 23403 | 0.050 |
Why?
|
Endometrial Hyperplasia | 1 | 2021 | 97 | 0.050 |
Why?
|
Pulmonary Embolism | 1 | 2013 | 2376 | 0.050 |
Why?
|
Electrocoagulation | 1 | 2020 | 158 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 890 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2023 | 535 | 0.040 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 491 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12245 | 0.040 |
Why?
|
Suction | 1 | 2020 | 267 | 0.040 |
Why?
|
Health Priorities | 1 | 2022 | 380 | 0.040 |
Why?
|
Mice, SCID | 1 | 2014 | 2716 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 1142 | 0.040 |
Why?
|
Time Factors | 3 | 2015 | 40075 | 0.040 |
Why?
|
Postoperative Complications | 2 | 2021 | 15295 | 0.040 |
Why?
|
New England | 1 | 2010 | 1022 | 0.040 |
Why?
|
Aminopterin | 1 | 2016 | 15 | 0.040 |
Why?
|
Parity | 1 | 2010 | 929 | 0.040 |
Why?
|
Aftercare | 1 | 2023 | 866 | 0.040 |
Why?
|
Algorithms | 1 | 2016 | 13881 | 0.030 |
Why?
|
Cell Count | 1 | 2010 | 1856 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2014 | 3557 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1788 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 806 | 0.030 |
Why?
|
Laparotomy | 1 | 2017 | 473 | 0.030 |
Why?
|
Remission Induction | 1 | 2010 | 2386 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2012 | 1076 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2938 | 0.030 |
Why?
|
Lower Extremity | 1 | 2022 | 1158 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2015 | 520 | 0.030 |
Why?
|
Papillomavirus Infections | 1 | 2015 | 1587 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2016 | 39050 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1405 | 0.030 |
Why?
|
Age Factors | 3 | 2015 | 18370 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 5172 | 0.030 |
Why?
|
Knee Joint | 1 | 2022 | 1680 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2016 | 2327 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2013 | 11727 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2022 | 5078 | 0.030 |
Why?
|
Male | 4 | 2023 | 350118 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2021 | 19905 | 0.020 |
Why?
|
Odds Ratio | 1 | 2023 | 9849 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11366 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2014 | 662 | 0.020 |
Why?
|
Emotions | 1 | 2022 | 2661 | 0.020 |
Why?
|
Neutropenia | 1 | 2015 | 895 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 35421 | 0.020 |
Why?
|
Logistic Models | 2 | 2014 | 13408 | 0.020 |
Why?
|
Heart Failure | 1 | 2013 | 10900 | 0.020 |
Why?
|
Low Back Pain | 1 | 2017 | 956 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1915 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.020 |
Why?
|
Medicare | 2 | 2015 | 6566 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 23338 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4933 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2022 | 4371 | 0.020 |
Why?
|
Quality Improvement | 1 | 2021 | 3749 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4851 | 0.020 |
Why?
|
Anemia | 1 | 2015 | 1506 | 0.020 |
Why?
|
Laparoscopy | 1 | 2017 | 2151 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13695 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2024 | 5686 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10252 | 0.010 |
Why?
|
Heart Rate | 1 | 2014 | 4091 | 0.010 |
Why?
|
Health Status | 1 | 2015 | 4034 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2013 | 1797 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9687 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14722 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12959 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 29786 | 0.010 |
Why?
|
Blood Pressure | 1 | 2014 | 8554 | 0.010 |
Why?
|
Registries | 1 | 2013 | 8089 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2014 | 20822 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 20947 | 0.010 |
Why?
|
Mice | 1 | 2014 | 81183 | 0.010 |
Why?
|
Adolescent | 1 | 2014 | 85781 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 21746 | 0.010 |
Why?
|
Animals | 1 | 2014 | 168757 | 0.010 |
Why?
|